http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 14 Jan 2026 06:55:55 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+Comments/MindMed+%28MNMD%29+Reiterated+at+Overweight+by+Cantor+Fitzgerald%3A+Will+Outperform/25846376.html <p>Cantor Fitzgerald analyst Pete Stavropoulos reiterated an Overweight rating on MindMed (NASDAQ: MNMD).</p><p>The analyst commented, "We are bullish on the DT120 GAD and MDD P3 readouts → DT120 delivered clinically meaningful, stat sig, and durable responses on the HAM-A and MADRS scales out to wk-12 after a single dose in the P2b pbo-controlled trial. Should DT120 ODT deliver similar efficacy in the P3 GAD studies as seen in the P2b, we see it becoming a highly relevant therapeutic option that will shift the treatment paradigm to intermittent from chronic dosing, especially for patients who fail SoC. We estimate $1.7B in http://www.streetinsider.com/Analyst+Comments/MindMed+%28MNMD%29+Reiterated+at+Overweight+by+Cantor+Fitzgerald%3A+Will+Outperform/25846376.html Wed, 14 Jan 2026 06:55:55 -0500 MNMD http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Mind+Medicine+%28MindMed%29+++For%3A+Jan+09/25834826.html si-local-file:///var/storage/secattach/20260112/25834826.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Mind+Medicine+%28MindMed%29+++For%3A+Jan+09/25834826.html Mon, 12 Jan 2026 08:25:00 -0500 MNMD O.12458983 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Mind+Medicine+%28MindMed%29+++For%3A+Jan+09/25834826.html si-local-file:///var/storage/secattach/20260112/25834826.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Mind+Medicine+%28MindMed%29+++For%3A+Jan+09/25834826.html Mon, 12 Jan 2026 08:25:00 -0500 MNMD O.12458983 http://www.streetinsider.com/Analyst+Comments/Needham+Names+MindMed+%28MNMD%29+New+Top+Pick+for+2026%2C+Adds+to+Conviction+List/25801230.html <p>Needham analyst Ami Fadia reiterated a Hold rating and $28.00 price target on MindMed (NASDAQ: MNMD).</p><p>The analyst comments "We highlight MNMD as our Top Pick for 2026 and add it to Needham’s Conviction List. At current levels, we see an attractive risk-reward, driven by five pillars: Catalyst-rich 2026: Three pivotal readouts (2 in GAD and 1 in MDD) positioning 2026 as a transformative year. De-risked lead asset: MM120 de-risked in GAD based on robust Phase 2b and reasonably de-risked in MDD, supported by well-designed Phase 3s programs. Large TAM opportunity: Between GAD and MDD we see MM120 scaling to ~$2.5B+ http://www.streetinsider.com/Analyst+Comments/Needham+Names+MindMed+%28MNMD%29+New+Top+Pick+for+2026%2C+Adds+to+Conviction+List/25801230.html Mon, 05 Jan 2026 07:08:39 -0500 ACAD AXSM CNTA MNMD PRAX http://www.streetinsider.com/Analyst+Comments/Needham+Names+MindMed+%28MNMD%29+New+Top+Pick+for+2026%2C+Adds+to+Conviction+List/25801230.html <p>Needham analyst Ami Fadia reiterated a Hold rating and $28.00 price target on MindMed (NASDAQ: MNMD).</p><p>The analyst comments "We highlight MNMD as our Top Pick for 2026 and add it to Needham’s Conviction List. At current levels, we see an attractive risk-reward, driven by five pillars: Catalyst-rich 2026: Three pivotal readouts (2 in GAD and 1 in MDD) positioning 2026 as a transformative year. De-risked lead asset: MM120 de-risked in GAD based on robust Phase 2b and reasonably de-risked in MDD, supported by well-designed Phase 3s programs. Large TAM opportunity: Between GAD and MDD we see MM120 scaling to ~$2.5B+ http://www.streetinsider.com/Analyst+Comments/Needham+Names+MindMed+%28MNMD%29+New+Top+Pick+for+2026%2C+Adds+to+Conviction+List/25801230.html Mon, 05 Jan 2026 07:08:39 -0500 ACAD AXSM CNTA MNMD PRAX http://www.streetinsider.com/Analyst+Comments/Needham+Names+MindMed+%28MNMD%29+New+Top+Pick+for+2026%2C+Adds+to+Conviction+List/25801230.html <p>Needham analyst Ami Fadia reiterated a Hold rating and $28.00 price target on MindMed (NASDAQ: MNMD).</p><p>The analyst comments "We highlight MNMD as our Top Pick for 2026 and add it to Needham’s Conviction List. At current levels, we see an attractive risk-reward, driven by five pillars: Catalyst-rich 2026: Three pivotal readouts (2 in GAD and 1 in MDD) positioning 2026 as a transformative year. De-risked lead asset: MM120 de-risked in GAD based on robust Phase 2b and reasonably de-risked in MDD, supported by well-designed Phase 3s programs. Large TAM opportunity: Between GAD and MDD we see MM120 scaling to ~$2.5B+ http://www.streetinsider.com/Analyst+Comments/Needham+Names+MindMed+%28MNMD%29+New+Top+Pick+for+2026%2C+Adds+to+Conviction+List/25801230.html Mon, 05 Jan 2026 07:08:39 -0500 ACAD AXSM CNTA MNMD PRAX http://www.streetinsider.com/Analyst+Comments/Needham+Names+MindMed+%28MNMD%29+New+Top+Pick+for+2026%2C+Adds+to+Conviction+List/25801230.html <p>Needham analyst Ami Fadia reiterated a Hold rating and $28.00 price target on MindMed (NASDAQ: MNMD).</p><p>The analyst comments "We highlight MNMD as our Top Pick for 2026 and add it to Needham’s Conviction List. At current levels, we see an attractive risk-reward, driven by five pillars: Catalyst-rich 2026: Three pivotal readouts (2 in GAD and 1 in MDD) positioning 2026 as a transformative year. De-risked lead asset: MM120 de-risked in GAD based on robust Phase 2b and reasonably de-risked in MDD, supported by well-designed Phase 3s programs. Large TAM opportunity: Between GAD and MDD we see MM120 scaling to ~$2.5B+ http://www.streetinsider.com/Analyst+Comments/Needham+Names+MindMed+%28MNMD%29+New+Top+Pick+for+2026%2C+Adds+to+Conviction+List/25801230.html Mon, 05 Jan 2026 07:08:39 -0500 ACAD AXSM CNTA MNMD PRAX http://www.streetinsider.com/Analyst+Comments/Needham+Names+MindMed+%28MNMD%29+New+Top+Pick+for+2026%2C+Adds+to+Conviction+List/25801230.html <p>Needham analyst Ami Fadia reiterated a Hold rating and $28.00 price target on MindMed (NASDAQ: MNMD).</p><p>The analyst comments "We highlight MNMD as our Top Pick for 2026 and add it to Needham’s Conviction List. At current levels, we see an attractive risk-reward, driven by five pillars: Catalyst-rich 2026: Three pivotal readouts (2 in GAD and 1 in MDD) positioning 2026 as a transformative year. De-risked lead asset: MM120 de-risked in GAD based on robust Phase 2b and reasonably de-risked in MDD, supported by well-designed Phase 3s programs. Large TAM opportunity: Between GAD and MDD we see MM120 scaling to ~$2.5B+ http://www.streetinsider.com/Analyst+Comments/Needham+Names+MindMed+%28MNMD%29+New+Top+Pick+for+2026%2C+Adds+to+Conviction+List/25801230.html Mon, 05 Jan 2026 07:08:39 -0500 ACAD AXSM CNTA MNMD PRAX http://www.streetinsider.com/Hot+Comments/Needham+Names+MindMed+%28MNMD%29+New+Top+Pick+for+2026%2C+Adds+to+Conviction+List/25801230.html <p>Needham analyst Ami Fadia reiterated a Hold rating and $28.00 price target on MindMed (NASDAQ: MNMD).</p><p>The analyst comments "We highlight MNMD as our Top Pick for 2026 and add it to Needham’s Conviction List. At current levels, we see an attractive risk-reward, driven by five pillars: Catalyst-rich 2026: Three pivotal readouts (2 in GAD and 1 in MDD) positioning 2026 as a transformative year. De-risked lead asset: MM120 de-risked in GAD based on robust Phase 2b and reasonably de-risked in MDD, supported by well-designed Phase 3s programs. Large TAM opportunity: Between GAD and MDD we see MM120 scaling to ~$2.5B+ http://www.streetinsider.com/Hot+Comments/Needham+Names+MindMed+%28MNMD%29+New+Top+Pick+for+2026%2C+Adds+to+Conviction+List/25801230.html Mon, 05 Jan 2026 07:08:39 -0500 ACAD AXSM CNTA MNMD PRAX http://www.streetinsider.com/Hot+Comments/Needham+Names+MindMed+%28MNMD%29+New+Top+Pick+for+2026%2C+Adds+to+Conviction+List/25801230.html <p>Needham analyst Ami Fadia reiterated a Hold rating and $28.00 price target on MindMed (NASDAQ: MNMD).</p><p>The analyst comments "We highlight MNMD as our Top Pick for 2026 and add it to Needham’s Conviction List. At current levels, we see an attractive risk-reward, driven by five pillars: Catalyst-rich 2026: Three pivotal readouts (2 in GAD and 1 in MDD) positioning 2026 as a transformative year. De-risked lead asset: MM120 de-risked in GAD based on robust Phase 2b and reasonably de-risked in MDD, supported by well-designed Phase 3s programs. Large TAM opportunity: Between GAD and MDD we see MM120 scaling to ~$2.5B+ http://www.streetinsider.com/Hot+Comments/Needham+Names+MindMed+%28MNMD%29+New+Top+Pick+for+2026%2C+Adds+to+Conviction+List/25801230.html Mon, 05 Jan 2026 07:08:39 -0500 ACAD AXSM CNTA MNMD PRAX http://www.streetinsider.com/Hot+Comments/Needham+Names+MindMed+%28MNMD%29+New+Top+Pick+for+2026%2C+Adds+to+Conviction+List/25801230.html <p>Needham analyst Ami Fadia reiterated a Hold rating and $28.00 price target on MindMed (NASDAQ: MNMD).</p><p>The analyst comments "We highlight MNMD as our Top Pick for 2026 and add it to Needham’s Conviction List. At current levels, we see an attractive risk-reward, driven by five pillars: Catalyst-rich 2026: Three pivotal readouts (2 in GAD and 1 in MDD) positioning 2026 as a transformative year. De-risked lead asset: MM120 de-risked in GAD based on robust Phase 2b and reasonably de-risked in MDD, supported by well-designed Phase 3s programs. Large TAM opportunity: Between GAD and MDD we see MM120 scaling to ~$2.5B+ http://www.streetinsider.com/Hot+Comments/Needham+Names+MindMed+%28MNMD%29+New+Top+Pick+for+2026%2C+Adds+to+Conviction+List/25801230.html Mon, 05 Jan 2026 07:08:39 -0500 ACAD AXSM CNTA MNMD PRAX http://www.streetinsider.com/Hot+Comments/Needham+Names+MindMed+%28MNMD%29+New+Top+Pick+for+2026%2C+Adds+to+Conviction+List/25801230.html <p>Needham analyst Ami Fadia reiterated a Hold rating and $28.00 price target on MindMed (NASDAQ: MNMD).</p><p>The analyst comments "We highlight MNMD as our Top Pick for 2026 and add it to Needham’s Conviction List. At current levels, we see an attractive risk-reward, driven by five pillars: Catalyst-rich 2026: Three pivotal readouts (2 in GAD and 1 in MDD) positioning 2026 as a transformative year. De-risked lead asset: MM120 de-risked in GAD based on robust Phase 2b and reasonably de-risked in MDD, supported by well-designed Phase 3s programs. Large TAM opportunity: Between GAD and MDD we see MM120 scaling to ~$2.5B+ http://www.streetinsider.com/Hot+Comments/Needham+Names+MindMed+%28MNMD%29+New+Top+Pick+for+2026%2C+Adds+to+Conviction+List/25801230.html Mon, 05 Jan 2026 07:08:39 -0500 ACAD AXSM CNTA MNMD PRAX http://www.streetinsider.com/Hot+Comments/Needham+Names+MindMed+%28MNMD%29+New+Top+Pick+for+2026%2C+Adds+to+Conviction+List/25801230.html <p>Needham analyst Ami Fadia reiterated a Hold rating and $28.00 price target on MindMed (NASDAQ: MNMD).</p><p>The analyst comments "We highlight MNMD as our Top Pick for 2026 and add it to Needham’s Conviction List. At current levels, we see an attractive risk-reward, driven by five pillars: Catalyst-rich 2026: Three pivotal readouts (2 in GAD and 1 in MDD) positioning 2026 as a transformative year. De-risked lead asset: MM120 de-risked in GAD based on robust Phase 2b and reasonably de-risked in MDD, supported by well-designed Phase 3s programs. Large TAM opportunity: Between GAD and MDD we see MM120 scaling to ~$2.5B+ http://www.streetinsider.com/Hot+Comments/Needham+Names+MindMed+%28MNMD%29+New+Top+Pick+for+2026%2C+Adds+to+Conviction+List/25801230.html Mon, 05 Jan 2026 07:08:39 -0500 ACAD AXSM CNTA MNMD PRAX http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Mind+Medicine+%28MindMed%29+++For%3A+Dec+26++Filed+by%3A+Barrow+Robert/25786753.html si-local-file:///var/storage/secattach/20251229/25786753.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Mind+Medicine+%28MindMed%29+++For%3A+Dec+26++Filed+by%3A+Barrow+Robert/25786753.html Mon, 29 Dec 2025 17:00:00 -0500 MNMD O.12458983 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Mind+Medicine+%28MindMed%29+++For%3A+Dec+26++Filed+by%3A+Barrow+Robert/25786753.html si-local-file:///var/storage/secattach/20251229/25786753.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Mind+Medicine+%28MindMed%29+++For%3A+Dec+26++Filed+by%3A+Barrow+Robert/25786753.html Mon, 29 Dec 2025 17:00:00 -0500 MNMD O.12458983 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Mind+Medicine+%28MindMed%29+++For%3A+Dec+26++Filed+by%3A+Sullivan+Mark/25786754.html si-local-file:///var/storage/secattach/20251229/25786754.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Mind+Medicine+%28MindMed%29+++For%3A+Dec+26++Filed+by%3A+Sullivan+Mark/25786754.html Mon, 29 Dec 2025 17:00:00 -0500 MNMD O.12458983 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Mind+Medicine+%28MindMed%29+++For%3A+Dec+26++Filed+by%3A+Sullivan+Mark/25786754.html si-local-file:///var/storage/secattach/20251229/25786754.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Mind+Medicine+%28MindMed%29+++For%3A+Dec+26++Filed+by%3A+Sullivan+Mark/25786754.html Mon, 29 Dec 2025 17:00:00 -0500 MNMD O.12458983 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Mind+Medicine+%28MindMed%29+++For%3A+Dec+26++Filed+by%3A+Karlin+Daniel/25786756.html si-local-file:///var/storage/secattach/20251229/25786756.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Mind+Medicine+%28MindMed%29+++For%3A+Dec+26++Filed+by%3A+Karlin+Daniel/25786756.html Mon, 29 Dec 2025 17:00:00 -0500 MNMD O.12458983 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Mind+Medicine+%28MindMed%29+++For%3A+Dec+26++Filed+by%3A+Karlin+Daniel/25786756.html si-local-file:///var/storage/secattach/20251229/25786756.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Mind+Medicine+%28MindMed%29+++For%3A+Dec+26++Filed+by%3A+Karlin+Daniel/25786756.html Mon, 29 Dec 2025 17:00:00 -0500 MNMD O.12458983 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Mind+Medicine+%28MindMed%29++++++++++++++++Filed+by%3A+Karlin+Daniel/25786233.html si-local-file:///var/storage/secattach/20251229/25786233.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Mind+Medicine+%28MindMed%29++++++++++++++++Filed+by%3A+Karlin+Daniel/25786233.html Mon, 29 Dec 2025 16:16:00 -0500 MNMD O.12458983 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Mind+Medicine+%28MindMed%29++++++++++++++++Filed+by%3A+Karlin+Daniel/25786233.html si-local-file:///var/storage/secattach/20251229/25786233.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Mind+Medicine+%28MindMed%29++++++++++++++++Filed+by%3A+Karlin+Daniel/25786233.html Mon, 29 Dec 2025 16:16:00 -0500 MNMD O.12458983 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Mind+Medicine+%28MindMed%29++++++++++++++++Filed+by%3A+Barrow+Robert/25786189.html si-local-file:///var/storage/secattach/20251229/25786189.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Mind+Medicine+%28MindMed%29++++++++++++++++Filed+by%3A+Barrow+Robert/25786189.html Mon, 29 Dec 2025 16:15:00 -0500 MNMD O.12458983 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Mind+Medicine+%28MindMed%29++++++++++++++++Filed+by%3A+Barrow+Robert/25786189.html si-local-file:///var/storage/secattach/20251229/25786189.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Mind+Medicine+%28MindMed%29++++++++++++++++Filed+by%3A+Barrow+Robert/25786189.html Mon, 29 Dec 2025 16:15:00 -0500 MNMD O.12458983 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Mind+Medicine+%28MindMed%29++++++++++++++++Filed+by%3A+Sullivan+Mark/25786203.html si-local-file:///var/storage/secattach/20251229/25786203.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Mind+Medicine+%28MindMed%29++++++++++++++++Filed+by%3A+Sullivan+Mark/25786203.html Mon, 29 Dec 2025 16:15:00 -0500 MNMD O.12458983 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Mind+Medicine+%28MindMed%29++++++++++++++++Filed+by%3A+Sullivan+Mark/25786203.html si-local-file:///var/storage/secattach/20251229/25786203.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Mind+Medicine+%28MindMed%29++++++++++++++++Filed+by%3A+Sullivan+Mark/25786203.html Mon, 29 Dec 2025 16:15:00 -0500 MNMD O.12458983